GanLi Pharmaceutical's Europe €700 million licensing deal speeds up exports of new GLP-1 drugs
A new overseas licensing deal could expand future GLP-1 drug supply into Europe.
Source →The trace
How it reaches your house.
Starting from GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) →Stands to benefitA. Menarini International Licensing S.A.
The licensee receives exclusive European registration and commercialization rights, so it is the direct beneficiary of the rollout.
“近日，甘李药业股份有限公司（以下简称“公司”）与A. Menarini International Licensing S.A.（以下简称“Menarini”）达成独家许可协议，授予Menarini在公司自主研发的博凡格鲁肽超重或肥胖适应症项目在授权区域内的上市注册及商业化的权利。”
92% confidenceCited →GLP-1 drugs (Ozempic, Wegovy, Mounjaro) →Stands to benefitA. Menarini International Licensing S.A.
Menarini received exclusive development and commercialization rights across Europe for GanLi's bofangruglutide, making it the direct beneficiary of the licensing deal.
“根据协议，甘李药业公司将博凡格鲁肽在欧盟27个成员国及英国、瑞士、挪威、冰岛、列支敦士登、巴尔干地区等共计39个欧洲国家和地区的开发及商业化独家权利有偿许可给Menarini。”
91% confidenceCited →
Where it lands
What you buy, and what you own.
Goods you buy
GLP-1 drugs (Ozempic, Wegovy, Mounjaro)
Companies you may own
A. Menarini International Licensing S.A.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.